Head to head
Lixisenatide against Exenatide
Once daily against twice daily among the short-acting GLP-1 agonists, tested directly. Both have largely been displaced by weekly drugs, which makes this a page about how the class was actually settled rather than about what most people are prescribed now.
Column A
LixisenatideLixisenatide (GLP-1 receptor agonist)
An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes, also studied for effects beyond glucose control.
Column B
ExenatideExenatide (GLP-1 receptor agonist)
The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class.
These two were tested against each other directly
A head to head trial, not two separate records compared by us.
HbA1c fell 0.79 percent on lixisenatide against 0.96 percent on exenatide, a treatment difference of 0.17 percentage points (95% CI 0.033 to 0.297), inside the predefined 0.4 point non-inferiority margin. Weight fell from 94.5 to 91.7 kg on lixisenatide and from 96.7 to 92.9 kg on exenatide. Symptomatic hypoglycaemia occurred in 2.5 percent against 7.9 percent and nausea in 24.5 percent against 35.1 percent, both favouring lixisenatide.
What the trial was
24 week, randomised, open-label, active-controlled, parallel-group multicentre study. 634 adults with type 2 diabetes inadequately controlled on metformin, HbA1c between 7 and 10 percent, randomised to lixisenatide 20 micrograms once daily (318) or exenatide 10 micrograms twice daily (316). The primary objective was non-inferiority of lixisenatide for HbA1c change at week 24.
What the authors concluded
The authors conclude that lixisenatide once daily was non-inferior on HbA1c with slightly lower mean weight loss, less hypoglycaemia and better gastrointestinal tolerability than exenatide twice daily.
Where this result is weak
Open-label and 24 weeks, with HbA1c as the endpoint. The comparator is exenatide in its twice-daily form, not the once-weekly formulation most people encounter now, so the result does not transfer to that product. Both a non-inferiority margin and an open-label design favour the newer drug when tolerability is being reported by unblinded participants.
Side by side, on the facts we can check
| Attribute | Lixisenatide | Exenatide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Adlyxin) | FDA-approved (Byetta, Bydureon) |
| Half-life | ~3 hours | ~2.4 hours (immediate release) |
| Molecular weight | 4,858.5 Da | 4,186.6 Da |
| Mechanism | Activates the GLP-1 receptor, enhancing glucose-dependent insulin release and markedly slowing gastric emptying to blunt post-meal glucose. | Agonizes the GLP-1 receptor with roughly 53% homology to human GLP-1, enhancing insulin secretion, reducing glucagon, and slowing gastric emptying. |
| Human studies cited | 2 | 2 |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Lixisenatide and Exenatide?
Lixisenatide: An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes, also studied for effects beyond glucose control. Exenatide: The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class.
Which has stronger research evidence, Lixisenatide or Exenatide?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the Lixisenatide profile were human work, against 2 of 3 for Exenatide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Lixisenatide and Exenatide FDA-approved?
Lixisenatide: FDA-approved (Adlyxin). Exenatide: FDA-approved (Byetta, Bydureon).
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.